Bio-Techne stock kpis
Want to see TECH full AI Analyst Report?
Operating Income by Segment
Bio-Techne reported operating income by segment of $83.20M in Q1 FY2027, down 14.3% from Q4 FY2026 and up 7.1% year over year. The highest value was $103.91M in Q3 FY2025.
Reports each segment’s profit after operating costs, revealing which parts of the business cover their overhead and contribute to core profitability. Tracking these trends shows whether growth is coming from efficient, scalable operations or from lower-margin areas that may need restructuring.
Protein Sciences' operating income shows consistent seasonality—repeated strong Q1 peaks and recurring Q3 troughs—while peak Q1s have crept higher through 2025–26, but Q3 lows have deepened, producing lumpy quarterly results. That pattern suggests demand tied to funding/ordering cycles rather than structural margin expansion; expect full-year stability but volatile quarter-to-quarter guidance risk. Investors should prioritize year-over-year and trailing-12-month trends and management commentary on order visibility rather than any single quarter.
TECH Operating Income by Segment
| Period | Protein Sciences |
|---|---|
| Q1 FY2027Sep 30, 2026 | $83.20M |
| Q4 FY2026Jun 30, 2026 | $97.07M |
| Q3 FY2026Mar 31, 2026 | $100.00M |
| Q2 FY2026Dec 31, 2025 | $84.61M |
| Q1 FY2026Sep 30, 2025 | $77.71M |
| Q4 FY2025Jun 30, 2025 | $98.79M |
| Q3 FY2025Mar 31, 2025 | $103.91M |
| Q2 FY2025Dec 31, 2024 | $87.11M |
| Q1 FY2025Sep 30, 2024 | $80.54M |
| Q4 FY2024Jun 30, 2024 | $92.00M |
| Q3 FY2024Mar 31, 2024 | $94.83M |
| Q2 FY2024Dec 31, 2023 | $79.59M |
| Q1 FY2024Sep 30, 2023 | $88.36M |
| Q4 FY2023Jun 30, 2023 | $99.65M |
| Q3 FY2023Mar 31, 2023 | $98.76M |
| Q2 FY2023Dec 31, 2022 | $89.34M |
| Q1 FY2023Sep 30, 2022 | $85.94M |
| Q4 FY2022Jun 30, 2022 | $97.49M |
| Q3 FY2022Mar 31, 2022 | $96.75M |
| Q2 FY2022Dec 31, 2021 | $93.28M |
| Q1 FY2022Sep 30, 2021 | $90.10M |
| Q4 FY2021Jun 30, 2021 | $90.44M |
| Q3 FY2021Mar 31, 2021 | $88.39M |
| Q2 FY2021Dec 31, 2020 | $80.25M |
| Q1 FY2021Sep 30, 2020 | $70.35M |

